1-4 of 4
commercial insurance
Close
Sort by
Journal Articles

Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients with Commercial Insurance in the United States

Naomi Sacks, PhD, Bridget Healey, MPH, Philip Cyr, MPH, Katharine Batt, MD MSc, Noreen Roth Henig, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3410.
https://doi.org/10.1182/blood-2019-127197
Published: 2019
Journal Articles

Cost of Care at NCI-Designated Comprehensive Cancer Centers Vs. Other Treatment Sites for Young Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL)

Julie A. Wolfson, MD MS, Smita Bhatia, MD MPH, Jill Ginsberg, MD, Laura Becker, MS, David Bernstein, Henry (Joe) Henk, PhD, Gary H. Lyman, MD MPH, FRCP, Paul Nathan, MD, Diane Puccetti, MD, Jennifer J. Wilkes, MD, Lena E. Winestone, MD, Kelly Kenzik, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3531.
https://doi.org/10.1182/blood-2018-99-110649
Published: 2018
Journal Articles

Beta-Thalassemia Treatment and Complications in Two Large US Insured Population Databases

Nancy Maserejian, ScD, Li Li, MS, Jin Wang, MS, William E. Hobbs, MDPhD, Catherine Madigan, MD
Journal: Blood
Blood (2015) 126 (23): 3278.
https://doi.org/10.1182/blood.V126.23.3278.3278
Published: 2015
Journal Articles

Are There Differences in Patient Characteristics, Treatment Patterns and Costs by Treatment Setting?

Stacey Dacosta Byfield, Carolina Reyes, Ph.D., Laura K Becker, MS, Art Small, MD
Journal: Blood
Blood (2012) 120 (21): 4259.
https://doi.org/10.1182/blood.V120.21.4259.4259
Published: 2012